Related Experiment Videos
Estrogens, lipids, and heart disease
1Department of Community and Family Medicine (0607), University of California, San Diego, La Jolla 92093.
Insights
Hormone replacement therapy is not recommended for elderly women to prevent heart disease. Estrogen therapy may be considered for high-risk individuals, but its use requires careful case-by-case evaluation.
Area of Science:
- Geriatrics
- Cardiology
- Endocrinology
Background:
- Hormone replacement therapy (HRT) has been considered for various menopausal symptoms.
- The role of HRT in preventing cardiovascular disease in elderly women is debated.
- Established benefits include osteoporosis and urogenital atrophy prevention.
Purpose of the Study:
- To evaluate the indication of routine HRT for cardiovascular disease prevention in elderly women.
- To define appropriate patient selection for estrogen therapy.
- To address the complexities of HRT in women with an intact uterus.
Main Methods:
- Review of existing data on HRT and cardiovascular outcomes.
- Analysis of lipid profile changes with unopposed oral estrogen.
- Consideration of progestin's effects and patient preferences.
Main Results:
- Routine HRT for heart disease prevention in elderly women is not indicated.
- Estrogen therapy may be reserved for high-risk women (abnormal LDL/HDL or established coronary heart disease).
- Unopposed oral estrogen can improve lipoproteins, potentially reducing risk.
Conclusions:
- HRT is not routinely indicated for cardiovascular prevention in elderly women.
- Estrogen use for heart disease prevention should be individualized based on risk factors.
- Management decisions for HRT, especially with an intact uterus, require careful consideration of risks, benefits, and patient factors.
Abstract:
The routine prescription of hormone replacement therapy for elderly women to prevent heart disease is not indicated. Until better data are available, the use of estrogens primarily to prevent heart disease probably should be reserved for women at high risk by virtue of their LDL/HDL ratio or the presence of manifest coronary heart disease. There is no reason to give progestins to the woman without a uterus; unopposed oral estrogen should improve lipoproteins within a few weeks, and this change, if sustained, should reduce risk. The management of a woman with an intact uterus is more problematic given the unknowns about progestin's long-term effects on lipids or the heart and the unwillingness of many elderly women to resume regular (or irregular) bleeding. There are, however, many proven benefits of hormone replacement therapy, including the prevention of osteoporosis and urogenital atrophy. Decisions about when it is too late to start estrogen, or when it is time to stop it, will need to be made on a case-by-case basis.